Dr. Habibi has served as Vice President and Head of Safety & Pharmacovigilance of Eledon since February 2025, where she leads the company’s global safety and pharmacovigilance activities across its clinical programs. Prior to joining Eledon, Dr. Habibi held senior safety and pharmacovigilance leadership roles at CRISPR Therapeutics and Regenxbio, where she built high-performing global safety organizations and led global safety strategies for innovative therapeutics throughout clinical development and postmarketing stages. Over more than 20 years in global pharmacovigilance, she has directed safety strategy across a broad range of therapeutic areas, including oncology, gene therapy, gastroenterology, ophthalmology, rare diseases, and transplantation. Dr. Habibi earned her Doctor of Medicine from Shiraz University, School of Medicine and Healthcare Sciences, in Iran, and practiced family medicine before transitioning to a career in clinical research.
Transforming Lives. One Organ at a Time.